Tenax Therapeutics expects topline Phase 3 LEVEL trial results in August 2026

Tenax Therapeutics, Inc.

Tenax Therapeutics, Inc.

TENX

0.00
  • Tenax Therapeutics flagged August 2026 topline results for its Phase 3 LEVEL trial of TNX-103 (oral levosimendan) in PH-HFpEF.
  • LEVEL data is slated for a late-breaking presentation at ESC Congress 2026 on Aug. 29 in Munich.
  • The registrational trial enrolled over 230 patients, completed in March 2026.
  • A prespecified blinded sample size re-estimation in December 2025 indicated over 90% power to detect a 25-meter 6MWD change.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tenax Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-293485), on July 02, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.